Cidara Therapeutics

CDTX

Market cap $1.64B

Overview Fund Activity

64.71 USD

-2.20

3.29%

At close Updated Sep 16, 4:00 PM EDT

Pre-market

After hours

64.71

0.00

0%

1 day

-3.29%

5 days

2.62%

1 month

2.32%

3 months

188.76%

6 months

190.57%

Year to date

137.03%

1 year

448.39%

5 years

0.17%

10 years

-77.76%

About: Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.

Employees: 73

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

775% more first-time investments, than exits

New positions opened: 70 | Existing positions closed: 8

513% more capital invested

Capital invested by funds: $206M [Q1] → $1.26B (+$1.06B) [Q2]

383% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 6

200% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 9 (+6) [Q2]

135% more funds holding

Funds holding: 46 [Q1] → 108 (+62) [Q2]

34.05% more ownership

Funds ownership: 87.3% [Q1] → 121.35% (+34.05%) [Q2]

58% less call options, than puts

Call options by funds: $38M | Put options by funds: $90.5M

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$45

30% downside

Avg. target

$65

0% upside

High target

$75

16% upside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

JMP Securities Roy Buchanan	$66	Market Outperform Maintained	8 Aug 2025
Needham Joseph Stringer	$74	Buy Maintained	8 Aug 2025
HC Wainwright & Co. Sara Nik	$74	Buy Maintained	8 Aug 2025
RBC Capital Brian Abrahams	$75	Outperform Maintained	24 Jun 2025
Guggenheim Seamus Fernandez	$68	Buy Maintained	24 Jun 2025
HC Wainwright & Co. Joseph Pantginis	$53	Buy Maintained	24 Jun 2025
WBB Securities Steve Brozak	$45	Strong Buy Reiterated	23 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about CDTX published over the past 30 days

Cidara Therapeutics, Inc. (CDTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Cidara Therapeutics, Inc. (NASDAQ:CDTX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:00 AM EDT Company Participants Ryuk Byun - Managing Director Jeffrey Stein - President, CEO & Executive Director Frank Karbe - Chief Financial Officer Presentation Ryuk Byun Managing Director Good morning, everyone. Thank you very much for carving out time this morning to attend the Morgan Stanley Healthcare Conference.

Cidara Therapeutics, Inc. (CDTX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Cidara Therapeutics to Participate in September Investor Conferences

SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in the below September investor conferences.

Cidara Therapeutics to Participate in September Investor Conferences

Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting

SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced it will have two oral presentations, one of which is late-breaking, during the International Society for Respiratory Viruses (ISRV) 8th AntiViral Group (AVG) Meeting and 3rd International Meeting on Respiratory Pathogens (IMRP).

Cidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting

Cidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b Readout

Cidara Therapeutics, Inc.'s CD388's strong phase 2b results significantly de-risk CDTX and highlight its potential as a superior flu prophylactic, especially for high-risk patients. Multiple short-term catalysts—including FDA meeting, BARDA funding, potential early start of phase 3 and breakthrough designation—could accelerate development and drive further upside. Cidara is well-funded through phase 3, with $516.9M in cash, and is an attractive acquisition candidate after its impressive trial results.

Cidara Therapeutics: Still Big Catalysts Ahead Following Impressive Ph2b Readout

Cidara Therapeutics, Inc. (CDTX) Q2 2025 Earnings Call Transcript

Cidara Therapeutics, Inc. (NASDAQ:CDTX ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Frank L. Karbe - Chief Financial Officer Jeffrey L.

Cidara Therapeutics, Inc. (CDTX) Q2 2025 Earnings Call Transcript

The Motley Fool

Cidara (CDTX) Q2 Cash Surges 163%

Cidara (CDTX) Q2 Cash Surges 163%

Cidara (CDTX) Q2 Cash Surges 163%

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Phase 2b NAVIGATE clinical trial evaluating CD388 for the prevention of seasonal influenza met primary and all secondary efficacy endpoints for all dose groups End of Phase 2 meeting request submitted to the U.S. Food and Drug Administration (FDA) Closed upsized public offering for gross proceeds of $402.5 million; significantly strengthened balance sheet to conduct planned Phase 3 program for CD388 Added to Russell 2000 ® and Russell 3000 ® Indexes Conference call and webcast today at 5:00 PM Eastern Time SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company or Cidara), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today reported financial results for the second quarter ended June 30, 2025, and provided recent business updates. “The highly compelling results of our Phase 2b NAVIGATE trial for CD388 and subsequent financing puts us in a position of strength to execute on our Phase 3 plan to examine the potential of CD388, a non-vaccine solution, to provide single-dose per season, universal protection against influenza in individuals at greatest risk from influenza,” said Jeffrey Stein, Ph.D.

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025

SAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its second quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, August 7, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss the results and provide an update on business operations.

Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025

Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics

MIAMI LAKES, Fla.--(BUSINESS WIRE)-- #AntiviralTreatment--Segal Trials proudly announces its participation in the successful Phase 2b NAVIGATE clinical trial conducted by Cidara Therapeutics, evaluating CD388—a novel, non-vaccine, long-acting antiviral—for the prevention of seasonal influenza. Dr. Steven Chavoustie served as the Principal Investigator for the study at Segal Trials. The NAVIGATE trial enrolled over 5,000 healthy, unvaccinated adults and met both its primary and secondary efficacy endpoints, showing t.

Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics

Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the Compensation and Human Capital Committee of its Board of Directors (Compensation Committee) granted non-qualified stock option awards and restricted stock units (RSUs) for an aggregate of 12,100 shares of its common stock to two new employees, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, as amended (the Inducement Plan), with a grant date of June 30, 2025. The stock option has an exercise price of $48.71 per share, which is equal to the closing price of Cidara's common stock on the grant date. The shares subject to the option will vest over four years, with 25% of the shares vesting on the one-year anniversary of the vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter. All RSUs vest in four equal annual installments, with 1/4 vesting on each of the first, second, third and fourth anniversaries of the Quarterly Vesting Date (as defined below) that occurs during the calendar quarter that includes the date of grant. “Quarterly Vesting Date” means March 10, June 10, September 10 or December 10. The awards are subject to the award holder's continuous service through each vesting date and to the terms and conditions of the Inducement Plan and the standard forms of grant agreements thereunder.

Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

See News Rankings

Charts implemented using Lightweight Charts™